LONDON—Mundipharma International has appointed Cohn & Wolfe’s healthcare practice to provide European public relations support for its investigational pain treatment. The agency has also won a brief for the U.K. implementation of the campaign, from Mundipharma’s U.K. associate Napp Pharmaceuticals, following a three-way pitch.
Cohn & Wolfe will be responsible for developing a communications strategy for the pre-launch and launch of the PR oxycodone/naloxone combination tablet across Europe, including development of campaign collateral and ensuring consistency. The U.K. brief is to implement a public relations and medical education campaign around the launch of the drug.
The European account team will report into Jeremy Clark, business development director, while the U.K. team is headed up by director Jo Spadaccino.